A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 [lapatinib] in Combination With Trastuzumab [Herceptin]
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2012
At a glance
- Drugs Lapatinib; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2012 Actual end date (1 Feb 2005) added as reported by ClinicalTrials.gov.
- 21 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.